Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia

Key Inclusion Criteria: * Completed informed consent. * Subject has a primary diagnosis of schizophrenia. * The subject is experiencing an acute exacerbation or relapse of symptoms and currently requires hospitalization. * Subjects taking prohibited medications, including antipsychotics, must discontinue before study participation * Subject is willing and able to remain in an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements. Key Exclusion Criteria: * An unstable medical condition, chronic disease, or malignancy. * Considered by the investigator to be at imminent risk of suicide or injury to self or others. * Diagnosis of moderate or severe substance use disorder (with the exception of nicotine or caffeine dependence) within 6 months prior to screening. * Positive alcohol test or drug screen for disallowed substances. * Have a history of poor or suspected poor compliance in clinical research studies and/or in the investigator's opinion, the subject is not capable of adhering to the protocol requirements.